Valneva: big reduction in net loss in H1
(CercleFinance.com) - Vaccine company Valneva has reported a net loss of E35m for H1 2023, well below the E171.
5m a year ago, despite total annual sales falling from E93.2m to E73.7m.
Product sales more than doubled to E69.7m, boosted by sales of Ixiaro and Dukoral, which benefited from the continued recovery of the travel market and price increases.
Valneva has confirmed its financial outlook for 2023, including total sales and other operating income estimated at E220m to E260m, and R&D expenditure estimated at E70m to E90m.
Copyright (c) 2023 CercleFinance.com. All rights reserved.